Oppenheimer Appoints James Yoo Managing Director in Healthcare Equity Capital Markets Investment Banking
Oppenheimer Appoints James Yoo Managing Director in Healthcare Equity Capital Markets Investment Banking |
[06-October-2025] |
Seasoned industry professional brings 27 years of experience to expanding Healthcare platform NEW YORK, Oct. 6, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer") — a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — today announced that James Yoo has been named a Managing Director within its Healthcare Equity Capital Markets Investment Banking Group. In this role, Mr. Yoo will focus on Biotechnology Equity Capital Markets transactions. With 27 years of experience, Mr. Yoo has developed deep expertise in a range of financing structures, including Private Investment in Public Equity (PIPEs), Follow-on Offerings, Confidentially Marketed Public Offerings (CMPOs) and Registered Direct transactions. "James brings an exceptional track record of execution and deep relationships across the biotechnology investment community to his new role," said Peter Bennett, Managing Director and Head of Equity Capital Markets Investment Banking at Oppenheimer. "His ability to navigate complex financing structures will further strengthen Oppenheimer's leadership in Healthcare Equity Capital Markets." Before stepping into his new role, Mr. Yoo served as the Healthcare Specialist on Oppenheimer's Sales & Trading Desk since 2023, advising healthcare-dedicated investment funds and early- and late-stage biotechnology companies. Prior to Oppenheimer, he held various positions at leading firms such as Piper Sandler, Mizuho, and Nomura. "I am honored to join Oppenheimer's Healthcare Equity Capital Markets Investment Banking Group at such an exciting time for the biotechnology sector," Yoo said. "The firm's collaborative culture and broad platform create an exceptional environment to deliver innovative capital markets solutions. I look forward to working with my colleagues to help biotech companies access the financing they need to advance groundbreaking science and improve patient outcomes." About Oppenheimer Holdings Inc. Media Contact:
SOURCE Oppenheimer & Co. Inc. | ||
Company Codes: NYSE:OPY |